THERAPY DOSSIER · th-ca3715091451

Aminoguanidine

Drug · No ChEMBL mechanism record; known iNOS / advanced glycation end-product (AGE) inhibitor

Evidence & regulatory context

Mechanism: No ChEMBL mechanism record; known iNOS / advanced glycation end-product (AGE) inhibitor
Target: Not recorded
Injury models: Chemical/toxin
Reported indication: Not recorded
First approval: Not recorded
Development stage: In trials, not approved
ChEMBL record: CHEMBL225304 ↗
ChEMBL max phase: 2 / 4 (development scale, not regulatory approval)
Synonyms: Aminoguanidine; Pimagedine
Note: Not recorded

Clinical trials 2

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT02099981 ↗PHASE1completed

Restoration of Retinal Vascular Responses in Type 1 Diabetic Patients (Aminoguanidine)

Diabetic Retinopathy

Enrolment: 34 · Results not recorded

NCT00184990 ↗PHASE1completed

Effect of Selective iNOS Inhibition During Human Endotoxemia (Aminoguanidine)

Endotoxemia

Enrolment: 7 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 22981630 ↗2012Mixed findings

Attenuation of acute nitrogen mustard-induced lung injury, inflammation and fibrogenesis by a nitric oxide synthase inhibitor.

RatChemical/toxinWistarMalen = Minimum of 3 to 4 animals per treatment groupIntraperitoneal50 mg/kgBeginning one hour before nitrogen mustard exposure

Model: Intratracheal instillation of nitrogen mustard (mechlorethamine) 0.125 mg/kg

Aminoguanidine abrogated nitrogen mustard-induced injury, oxidative stress and inflammation at 1 and 3 days post exposure, but had no effect at 7 or 28 days and did not prevent pulmonary fibrosis.

Extraction: extract · Supplied extraction confidence: 0.9. Machine-extracted fields require source verification.

Loading the evidence…